Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trialMehdi Hamadani, Pier Luigi Zinzani, Kirit M. Ardeshna et al.|Blood Advances|2023Cited by 7
Long-term survival projections of loncastuximab tesirine-treated patients in relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).Mehdi Hamadani, Carmelo Carlo‐Stella, Christopher N. Graham et al.|Journal of Clinical Oncology|2022Cited by 0
ABCL-334 Long-Term Survival Projections of Loncastuximab Tesirine-Treated Patients in Relapsed or Refractory Diffuse Large B-Cell LymphomaMehdi Hamadani, Carmelo Carlo‐Stella, Christopher N. Graham et al.|Clinical Lymphoma Myeloma & Leukemia|2022Cited by 0
Poster: ABCL-334 Long-Term Survival Projections of Loncastuximab Tesirine-Treated Patients in Relapsed or Refractory Diffuse Large B-Cell LymphomaMehdi Hamadani, Carmelo Carlo‐Stella, Christopher N. Graham et al.|Clinical Lymphoma Myeloma & Leukemia|2022Cited by 0